Personalized PSMA radiotherapy for advanced PSMA-positive cancer
Part of Cancer, Kidney & urinary clinical trials.
This Phase 1/2 trial tests a personalized form of PSMA-targeted radiation therapy for adults with advanced cancers that strongly show PSMA on a PET scan. It may help shrink or control tumors by delivering radiation directly to PSMA-expressing cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (over 18) and able to give informed consent.
- Your cancer is inoperable or has spread, and it shows strong PSMA on a recent PET scan (at least one spot is brighter than the liver within 3 months).
- Your cancer has been growing or progressing within the last 3 months, and you have not started a new cancer treatment since then (except limited palliative radiation for small amounts).
- Your blood counts are high enough for treatment: platelets at least 50 (×10^6/L) and neutrophils at least 1.0 (×10^6/L).
- You do not have uncontrolled brain metastases that could cause complications, and you are not expected to have a very short prognosis (about 3 months or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
This trial tests whether adding a PSMA-targeted radioactive medicine (Lu-PSMA) to focused stereotactic radiation to a few prostate cancer spots works better than radiation alone. It may help people with limited, asymptomatic spread of prostate cancer by improving cancer control while carefully monitoring side effects.
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.